Dr. Chih-Kwang Sung, MD

Dr. Sung practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Sung's NPI, 1407019144, was assigned on July 2, 2008. Dr. Sung graduated from SUNY Downstate Health Sciences University in 2004. Dr. Sung holds California license A112816.

Dr. Sung's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Sung's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Sung to 1 more hospital and 1 medical group, each named with a free account. Dr. Sung's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sung practices, 2 sites in all. Vendor and product names are available with a free account.

Otolaryngology is Dr. Sung's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dr. Sung is board certified in otolaryngology by the American Board of Otolaryngology - Head and Neck Surgery. Dmand AI has Dr. Sung's licenses on file in 2 states: California and New York.

Dmand AI lists hearing loss and impairment, larynx and vocal cord disease and upper respiratory infection (URI) among the conditions Dr. Sung treats.

CMS data shows 755 Medicare services from Dr. Sung across 13 procedure codes in 2024, for 336 Medicare patients. Medicare paid $66,644 for them.

CMS counts 336 Medicare patients who saw Dr. Sung in 2024. The largest group is 65 to 74, with 144 patients. 75% of them have high cholesterol, and 67% have high blood pressure. 21% are also on Medicaid. Their average risk score is 1.68, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sung's median patient age at 64, with 53% women.

In 2024, Dr. Sung wrote 44 Medicare Part D claims for 26 patients. 95% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $79 in total drug cost. In 2022, CMS named 19 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Sung for performance year 2024, reported as part of a group. Dr. Sung accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sung as offering telehealth. CMS counts 17 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Sung, more than 48% of the clinicians it reports for that procedure.

Dmand AI links 44 papers to Dr. Sung, published from 2015 to 2025. 2018 was the busiest year, with 5. The most frequent topics are Head and Neck Neoplasms, Carcinoma, Squamous Cell and Voice Disorders. Dr. Sung has published most often in Laryngoscope. Dr. Sung's most frequent co-authors are Edward Joseph Damrose, MD, Eric M. Genden, MD and Shaun Chandra Desai, MD.

CMS Open Payments shows 4 general payments to Dr. Sung from 3 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 81% of the total. Gyrus ACMI, Inc. paid the most, $1,314.

Dmand AI lists 2 awards for Dr. Sung, most recently CMS Stage 1 EHR in 2013.

Dr. Sung graduated from SUNY Downstate Health Sciences University in 2004. Dr. Sung is a member of AOA, NHS, American Broncho-Esophalogical Association, Otolaryngology Program Directors Organization and Society of University Otolaryngologists.

Dr. Sung is in network with 9 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.